[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Ovarian Cancer: Epidemiology Forecast to 2028

July 2019 | 46 pages | ID: O4D1D24A6554EN
GlobalData

US$ 3,995.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Ovarian Cancer: Epidemiology Forecast to 2028

SUMMARY

Ovarian cancer is the most lethal gynecologic cancer and overall a leading cause of cancer incidence and mortality worldwide. The disease is defined as uncontrolled cell growth in the ovaries, although research has shown that the disease may actually originate in the fallopian tubes.

GlobalData epidemiologists used age%li%and sex-specific diagnosed incidence rates to forecast the diagnosed incident cases, and used the observed survival rates to calculate the five-year diagnosed prevalent cases, taking into account the significant relationship between age and ovarian cancer incidence, survival, and prevalence. GlobalData epidemiologists applied country-specific incidence rates of ovarian cancer, wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.

The following data describes epidemiology of ovarian cancer cases, including both cancer of the ovary and cancer of the fallopian tube. In 2018, the 7MM had 63,331 diagnosed incident cases of ovarian cancer. This is expected to increase to 66,000 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 0.42%. The increase is driven by changes in incidence rates in the 7MM. In 2018, the 7MM had 180,626 five-year diagnosed prevalent cases of ovarian cancer. This is expected to increase to 191,896 diagnosed prevalent cases by 2028, at an AGR of 0.62%. The US had the highest number of diagnosed incident and five-year diagnosed prevalent cases of ovarian cancer. The development of more effective screening tools for an early diagnosis, including a better understanding of the pathogenesis of the different histologic subtypes of ovarian cancer, would improve survival and increase disease prevalence.

SCOPE
  • The Ovarian Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of ovarian cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of ovarian cancer; five-year diagnosed prevalent cases of ovarian cancer; diagnosed incident cases of ovarian cancer by cancer stages at diagnosis; diagnosed incident cases of cancer of the ovary by histologic subtype; diagnosed incident cases of ovarian cancer by germline and somatic BRCA1/2 mutations; diagnosed incident cases of ovarian cancer with HRD; and diagnosed incident cases of epithelial ovarian cancer with FR? overexpression.
    • The ovarian cancer epidemiology report and model were written and developed by Masters%li%and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
REASONS TO BUY

The Ovarian Cancer Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global ovarian cancer market.
  • Quantify patient populations in the global ovarian cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for ovarian cancer therapeutics in each of the markets covered.
  • Understand magnitude of ovarian cancer population by mutations and associated biomarkers.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 OVARIAN CANCER: EXECUTIVE SUMMARY

2.1 Related Reports
2.2 Upcoming Reports

3 EPIDEMIOLOGY

3.1 Disease Background
3.2 Risk Factors
3.3 Global and Historical Trends
  3.3.1 7MM Trends in Diagnosed Incidence
  3.3.2 7MM Trends in Observed Survival
3.4 Forecast Methodology
  3.4.1 Sources
  3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Ovarian Cancer (2018-2028)
  3.5.1 Diagnosed Incident Cases of Ovarian Cancer
  3.5.2 Age-Specific Diagnosed Incidence of Ovarian Cancer
  3.5.3 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer
  3.5.4 Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis
  3.5.5 Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype
  3.5.6 Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation
  3.5.7 Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation
  3.5.8 Diagnosed Incident Cases of Ovarian Cancer with HRD
  3.5.9 Diagnosed Incident Cases of EOC with FR? Overexpression
3.6 Discussion
  3.6.1 Epidemiological Forecast Insight
  3.6.2 Limitations of Analysis
  3.6.3 Strengths of Analysis

4 APPENDIX

4.1 Bibliography
4.2 About the Authors
  4.2.1 Epidemiologist
  4.2.2 Reviewers
  4.2.3 Global Director of Therapy Analysis and Epidemiology
  4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer

LIST OF TABLES

Table 1: Risk Factors for Ovarian Cancer

The diagnosed incident cases of ovarian cancer in the seven major markets (7MM*) will increase at an annual growth rate (AGR) of 0.42% from over 63,000 cases in 2018 to 66,000 cases in 2028. All countries in the 7MM, except the US, will see a slight increase in diagnosed incident cases through the forecast period.

Our report found that in 2018, the US had the highest number of diagnosed incident and diagnosed prevalent cases of ovarian cancer.

Nanthida Nanthavong, Epidemiologist at GlobalData, comments:

“The decrease in incident cases in the US is due to an expected decrease in incidence rate during the forecast period for women ages 50 years and older, which can be attributed to decreased usage of menopausal hormones and increased usage of oral contraceptives, as well as changes in population. In the European markets and Japan, incidence will remain largely unchanged over the forecast period.”

‘Across all markets, diagnosing ovarian cancer continues to be difficult because symptoms can be non-specific and vague, resulting in a late diagnosis when the disease is in advanced stages.

Nanthavong concludes:

“The ability to detect ovarian cancer at an early stage is a research priority, as patients diagnosed at an early stage are estimated to have a significantly higher five-year survival rate than patients with a late-stage diagnosis.”



More Publications